Literature DB >> 24153155

Three novel mutations in the SLCO2A1 gene in two Chinese families with primary hypertrophic osteoarthropathy.

Ruhong Cheng1, Ming Li, Yifeng Guo, Yingjia Yao, Chunfang Gao, Zhirong Yao.   

Abstract

BACKGROUND: Primary hypertrophic osteoarthropathy (PHO (MIM 167100)) is a rare genetic disease characterized by pachyderma, periostosis and digital clubbing. Mutations in the 15-hydroxy-prostaglandin dehydrogenase (HPGD) gene and solute carrier organic anion transporter family member 2A1 (SLCO2A1) gene have been demonstrated to be pathogenic causes.
OBJECTIVE: We aimed to identify the genetic cause of 2 unrelated patients with PHO.
METHOD: Urinary levels of prostaglandin E2 and prostaglandin E metabolite were measured in Proband 1 and his sister by competitive ELISAs. Mutation analysis of the HPGD and SLCO2A1 genes were conducted on both probands with PHO. Genomic DNAs of 100 healthy controls were isolated and subjected to polymerase chain reaction and direct DNA sequencing. The identified mutations were further confirmed in the parents of Proband 1. Protein modeling and data from PolyPhen-2 were used to evaluate the effects of novel missense mutations on protein SLCO2A1.
RESULTS: The urinary levels of prostaglandin E2 and prostaglandin E metabolite in Proband 1 were much higher than those in unaffected individuals. Molecular genetic analysis revealed four SLCO2A1 mutations, including 3 novel ones (p.Arg603X, p.Gly183Arg and p.Asn534Lys) and a founder mutation, c.940+1G>A, in two probands with PHO. Missense mutations p.Gly183Arg and p.Asn534Lys, at highly conserved positions, were both predicted to be damaging. Protein modeling indicated that the mutation p.Gly183Arg altered the 3-dimensional structure of SLCO2A1.
CONCLUSIONS: Three novel mutations within the SLCO2A1 gene have been demonstrated to be associated with Chinese PHO patients.

Entities:  

Keywords:  mutation; primary hypertrophic osteoarthropathy; protein modeling; solute carrier organic anion transporter family member 2A1 gene

Mesh:

Substances:

Year:  2013        PMID: 24153155     DOI: 10.1684/ejd.2013.2154

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  6 in total

Review 1.  Roles of Organic Anion Transporting Polypeptide 2A1 (OATP2A1/SLCO2A1) in Regulating the Pathophysiological Actions of Prostaglandins.

Authors:  Takeo Nakanishi; Ikumi Tamai
Journal:  AAPS J       Date:  2017-12-04       Impact factor: 4.009

Review 2.  The Prostaglandin Transporter: Eicosanoid Reuptake, Control of Signaling, and Development of High-Affinity Inhibitors as Drug Candidates.

Authors:  Victor L Schuster; Yuling Chi; Run Lu
Journal:  Trans Am Clin Climatol Assoc       Date:  2015

3.  Inhibition of the Prostaglandin Transporter PGT Lowers Blood Pressure in Hypertensive Rats and Mice.

Authors:  Yuling Chi; Jean-Francois Jasmin; Yoshinori Seki; Michael P Lisanti; Maureen J Charron; David J Lefer; Victor L Schuster
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

4.  Characterization of Mineral and Bone Metabolism Biomarkers in a Chinese Consanguineous Twin Family with Primary Hypertrophic Osteoarthropathy.

Authors:  Na Li; Yuhang Ma; Yun Jiang; Li You; Yunhong Huang; Yongde Peng; Xiaoying Ding; Li Zhao
Journal:  Int J Endocrinol       Date:  2020-12-03       Impact factor: 3.257

5.  Identification of the Mutations in the Prostaglandin Transporter Gene, SLCO2A1 and Clinical Characterization in Korean Patients with Pachydermoperiostosis.

Authors:  Sihoon Lee; So Young Park; Hyun Jin Kwon; Chul-Ho Lee; Ok-Hwa Kim; Yumie Rhee
Journal:  J Korean Med Sci       Date:  2016-03-22       Impact factor: 2.153

6.  Interleukin-6, tumor necrosis factor-alpha and receptor activator of nuclear factor kappa ligand are elevated in hypertrophic gastric mucosa of pachydermoperiostosis.

Authors:  Hui Huang; Yongjun Wang; Yong Cao; Boda Wu; Yonggui Li; Liangliang Fan; Zhiping Tan; Yi Jiang; Jianguang Tang; Jianzhong Hu; Xiaoliu Shi
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.